This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
immunodeficiency virus | 2602 |
human immunodeficiency | 2382 |
hiv aids | 2007 |
hiv infection | 1813 |
public health | 1516 |
virus type | 1496 |
infectious diseases | 1354 |
virus infection | 1207 |
health care | 1192 |
immune response | 1181 |
blood donors | 1175 |
immune responses | 987 |
united states | 934 |
blood transfusion | 886 |
immune system | 831 |
infected patients | 826 |
influenza virus | 819 |
antiretroviral therapy | 808 |
acute respiratory | 790 |
antiviral activity | 775 |
viral replication | 766 |
risk factors | 764 |
infected cells | 762 |
whole blood | 738 |
viral load | 720 |
respiratory syndrome | 707 |
viral infections | 685 |
dendritic cells | 679 |
extracellular vesicles | 674 |
gene expression | 669 |
herpes simplex | 661 |
infectious disease | 652 |
red blood | 649 |
severe acute | 629 |
amino acid | 622 |
study design | 594 |
cell lines | 592 |
bone marrow | 578 |
clinical trials | 577 |
blood components | 572 |
viral infection | 572 |
summary conclusion | 570 |
infected individuals | 565 |
flow cytometry | 564 |
nucleic acid | 557 |
blood products | 552 |
doc id | 549 |
cord uid | 549 |
simplex virus | 544 |
blood donation | 544 |
cell surface | 538 |
virus replication | 534 |
case studies | 526 |
neutralizing antibodies | 518 |
mg kg | 517 |
host cell | 516 |
red cell | 512 |
ebola virus | 509 |
type i | 497 |
may also | 494 |
blood group | 493 |
blood cells | 493 |
summary conclusions | 490 |
pregnant women | 482 |
background case | 481 |
side effects | 476 |
class i | 471 |
breast milk | 465 |
world health | 462 |
reverse transcriptase | 456 |
viral rna | 450 |
peripheral blood | 443 |
stem cells | 435 |
stem cell | 435 |
blood bank | 434 |
significantly higher | 428 |
mental health | 423 |
monoclonal antibodies | 421 |
innate immune | 420 |
renal failure | 419 |
host cells | 418 |
respiratory tract | 414 |
viral proteins | 406 |
south africa | 403 |
drug resistance | 396 |
rna viruses | 393 |
health organization | 387 |
design method | 387 |
increased risk | 383 |
people living | 377 |
results finding | 375 |
control group | 373 |
cell responses | 370 |
mean age | 367 |
epithelial cells | 364 |
plasma membrane | 360 |
chronic hepatitis | 359 |
significant difference | 359 |
envelope glycoprotein | 357 |
cell culture | 356 |
hiv testing | 355 |
hiv transmission | 352 |
statistically significant | 352 |
cell line | 350 |
intensive care | 350 |
dengue virus | 348 |
amino acids | 347 |
adverse events | 345 |
target cells | 344 |
years old | 344 |
monoclonal antibody | 343 |
transfusion medicine | 343 |
blood cell | 340 |
important role | 339 |
hiv prevention | 336 |
hcv rna | 336 |
ng ml | 331 |
nervous system | 331 |
life cycle | 329 |
red cells | 328 |
performed using | 328 |
reverse transcription | 327 |
binding site | 327 |
hiv patients | 327 |
membrane fusion | 325 |
west nile | 325 |
developing countries | 325 |
saharan africa | 324 |
lateral flow | 319 |
blood pressure | 319 |
systematic review | 316 |
syndrome coronavirus | 315 |
blood donor | 313 |
mouse model | 313 |
cd cells | 311 |
cell count | 308 |
cd cd | 307 |
blood samples | 305 |
disease progression | 305 |
least one | 302 |
respiratory syncytial | 300 |
viral particles | 299 |
two groups | 299 |
barr virus | 295 |
general population | 295 |
high levels | 294 |
mg ml | 294 |
cohort study | 292 |
high risk | 289 |
cell death | 288 |
hcv infection | 285 |
syncytial virus | 284 |
nucleic acids | 283 |
animal models | 282 |
broadly neutralizing | 282 |
cell activation | 281 |
disease control | 279 |
nile virus | 278 |
protease inhibitors | 275 |
electron microscopy | 272 |
mg dl | 271 |
hiv infected | 271 |
risk factor | 271 |
central nervous | 270 |
cell types | 270 |
clinical trial | 268 |
vaccine development | 267 |
significant differences | 267 |
viral entry | 267 |
staphylococcus aureus | 263 |
enveloped viruses | 260 |
transplant recipients | 260 |
among hiv | 259 |
innate immunity | 259 |
zika virus | 256 |
virus entry | 255 |
cd cell | 255 |
abstract type | 255 |
renal function | 254 |
please specify | 254 |
antiviral agents | 250 |
human papillomavirus | 250 |
mycobacterium tuberculosis | 249 |
sex workers | 248 |
antiviral effect | 248 |
emergency department | 246 |
mass spectrometry | 246 |
platelet concentrates | 246 |
drug users | 245 |
antiviral drugs | 244 |
highly active | 243 |
transfusion reactions | 243 |
drug use | 240 |
rna interference | 239 |
data suggest | 239 |
case report | 239 |
health services | 236 |
urinary tract | 235 |
transfusion service | 235 |
global health | 234 |
time pcr | 234 |
chemokine receptor | 233 |
opportunistic infections | 232 |
present study | 232 |
pg ml | 231 |
rna polymerase | 231 |
new york | 230 |
western blot | 230 |
aids patients | 230 |
sexually transmitted | 229 |
first time | 227 |
results suggest | 226 |
dendritic cell | 226 |
per year | 226 |
fusion proteins | 225 |
quality control | 225 |
iu ml | 224 |
specific cd | 224 |
patients receiving | 224 |
adverse effects | 221 |
wild type | 221 |
room temperature | 221 |
infected children | 220 |
viral genome | 220 |
adaptive immune | 220 |
determine whether | 219 |
lymph nodes | 218 |
nephrotic syndrome | 218 |
class ii | 217 |
controlled trial | 217 |
breast cancer | 217 |
cell proliferation | 216 |
income countries | 216 |
growth factor | 216 |
care unit | 214 |
cancer cells | 214 |
informed consent | 214 |
immune cells | 212 |
blood banks | 212 |
viral envelope | 212 |
active antiretroviral | 212 |
endothelial cells | 212 |
humanized mice | 211 |
envelope protein | 210 |
virus infections | 210 |
gene therapy | 210 |
host immune | 209 |
renal disease | 209 |
recent years | 209 |
sars coronavirus | 209 |
mhc class | 209 |
binding protein | 208 |
human rights | 208 |
gold nanoparticles | 207 |
significantly lower | 207 |
clinical practice | 207 |
primary care | 205 |
neutralizing antibody | 205 |
blood donations | 205 |
heat shock | 205 |
vaccinia virus | 204 |
million people | 204 |
platelet count | 204 |
virus particles | 202 |
viral protein | 200 |
viral dna | 200 |
influenza viruses | 199 |
ex vivo | 199 |
positive patients | 199 |
tract infections | 198 |
among patients | 198 |
dna viruses | 198 |
hemorrhagic fever | 197 |
chain reaction | 196 |
logistic regression | 196 |
study period | 196 |
specific antibodies | 195 |
acquired immunodeficiency | 195 |
outcome measures | 195 |
simian immunodeficiency | 194 |
liver disease | 194 |
immunodeficiency syndrome | 194 |
blood supply | 193 |
hbv infection | 193 |
polymerase chain | 193 |
previous studies | 193 |
escherichia coli | 191 |
copies ml | 191 |
dependent manner | 189 |
blood collection | 189 |
prospective study | 188 |
mononuclear cells | 188 |
phase i | 188 |
sickle cell | 187 |
highly conserved | 187 |
hiv status | 187 |
patients treated | 187 |
cell membrane | 187 |
fusion protein | 186 |
wide range | 185 |
coronavirus disease | 185 |
even though | 185 |
stranded rna | 185 |
endoplasmic reticulum | 185 |
hiv positive | 185 |
one patient | 183 |
blood units | 183 |
aids epidemic | 182 |
blood center | 182 |
main outcome | 181 |
hbv dna | 181 |
lipid rafts | 181 |
two different | 181 |
recent study | 181 |
viral diseases | 181 |
antibody response | 180 |
immune activation | 180 |
antiviral therapy | 179 |
cell cycle | 178 |
university hospital | 178 |
weight loss | 177 |
streptococcus pneumoniae | 177 |
rhesus macaques | 177 |
clinically significant | 177 |
middle east | 176 |
factors associated | 176 |
total number | 176 |
hiv care | 175 |
infectious agents | 175 |
target cell | 175 |
protease inhibitor | 175 |
fusion peptide | 175 |
lower respiratory | 174 |
i interferon | 173 |
may lead | 173 |
cells expressing | 173 |
fever virus | 173 |
hiv disease | 172 |
immune reconstitution | 172 |
rna virus | 172 |
large number | 172 |
hiv vaccine | 171 |
leukemia virus | 171 |
antibody responses | 171 |
expression levels | 171 |
cancer patients | 170 |
global fund | 170 |
dna vaccine | 169 |
recent studies | 169 |
hong kong | 169 |
viral loads | 168 |
drug delivery | 168 |
high prevalence | 168 |
infection control | 168 |
also found | 168 |
long term | 168 |
vesicular stomatitis | 168 |
ml min | 167 |
antigen presentation | 167 |
inflammatory response | 167 |
hiv type | 167 |
commonly used | 167 |
plasma samples | 166 |
united kingdom | 166 |
significantly reduced | 165 |
immunocompromised patients | 165 |
medical center | 165 |
previously described | 165 |
human monoclonal | 165 |
emerging infectious | 164 |
mortality rate | 164 |
cd count | 164 |
novel coronavirus | 164 |
inhibitory effect | 163 |
phage display | 162 |
severe disease | 162 |
retrospective study | 162 |
may occur | 162 |
substance use | 161 |
results indicate | 161 |
dna vaccines | 160 |
protein expression | 160 |
young children | 160 |
patients infected | 160 |
blood product | 160 |
bacterial infections | 159 |
inflammatory cytokines | 159 |
oxidative stress | 158 |
study group | 158 |
molecular mechanisms | 158 |
clinical features | 158 |
inhibitory activity | 157 |
small molecule | 157 |
significantly increased | 157 |
kg day | 157 |
medical care | 157 |
hiv infections | 156 |
binding sites | 156 |
avian influenza | 156 |
cervical cancer | 155 |
yellow fever | 155 |
median age | 155 |
cord blood | 155 |
lung cancer | 154 |
nucleocapsid protein | 154 |
patients received | 154 |
two patients | 154 |
randomized controlled | 154 |
host factors | 154 |
silver nanoparticles | 154 |
human cytomegalovirus | 153 |
abstract background | 153 |
commercially available | 153 |
respiratory distress | 153 |
health system | 153 |
previously reported | 152 |
stomatitis virus | 152 |
results showed | 152 |
kidney disease | 152 |
several studies | 151 |
see table | 151 |
hiv replication | 151 |
research abstract | 151 |
patient care | 150 |
patients undergoing | 150 |
widely used | 150 |
first trimester | 150 |
hematopoietic stem | 150 |
bacterial contamination | 150 |
cell receptor | 149 |
cell fusion | 149 |
derived evs | 148 |
transfusion services | 148 |
child transmission | 148 |
cell counts | 148 |
bei der | 148 |
inhibit hiv | 148 |
transgenic mice | 147 |
south african | 147 |
envelope glycoproteins | 147 |
lentiviral vector | 147 |
necrosis factor | 146 |
statistical analysis | 145 |
tract infection | 145 |
conformational changes | 145 |
year old | 145 |
transcription factor | 145 |
last years | 144 |
care workers | 144 |
results findings | 144 |
small molecules | 144 |
study showed | 143 |
cytokine production | 143 |
high level | 143 |
design methods | 142 |
positive results | 142 |
nanoparticle tracking | 142 |
human cd | 142 |
blood safety | 141 |
viral hepatitis | 141 |
significant increase | 141 |
high affinity | 141 |
also known | 140 |
may result | 140 |
hiv prevalence | 140 |
shock protein | 140 |
tracking analysis | 139 |
acute renal | 139 |
mortality rates | 139 |
age group | 139 |
family members | 139 |
drug discovery | 139 |
immune deficiency | 138 |
combination therapy | 138 |
clinical symptoms | 138 |
type ii | 137 |
higher risk | 137 |
hiv activity | 137 |
data collection | 136 |
animal model | 136 |
signaling pathways | 136 |
vaccine design | 136 |
incubation period | 136 |
mesenchymal stem | 136 |
also observed | 135 |
crystal structure | 135 |
well tolerated | 135 |
human cells | 135 |
viral pathogens | 135 |
one year | 134 |
results show | 134 |
years ago | 134 |
adverse reactions | 133 |
health promotion | 133 |
cell response | 133 |
clinical studies | 133 |
blood component | 133 |
significantly associated | 133 |
body weight | 132 |
viral fusion | 132 |
respiratory infections | 132 |
hiv gp | 132 |
may contribute | 132 |
antiretroviral treatment | 132 |
protein kinase | 132 |
findings suggest | 132 |
encephalitis virus | 131 |
cryptococcal meningitis | 131 |
low levels | 131 |
test results | 131 |
cd counts | 131 |
cardiovascular disease | 131 |
may cause | 131 |
related stigma | 131 |
taken together | 131 |
surface expression | 130 |
bacterial pneumonia | 130 |
critically ill | 130 |
like receptor | 130 |
healthy controls | 130 |
three times | 130 |
vertical transmission | 129 |
drug interactions | 129 |
progressive multifocal | 129 |
fungal infections | 129 |
blood services | 129 |
molecular weight | 129 |
mammalian cells | 128 |
respiratory viruses | 128 |
health outcomes | 128 |
one study | 128 |
health systems | 128 |
early stage | 128 |
positive samples | 128 |
clinical outcomes | 127 |
viral suppression | 127 |
measles virus | 127 |
rbc units | 127 |
united nations | 126 |
patients without | 126 |
health workers | 126 |
may provide | 125 |
data indicate | 125 |
adult patients | 125 |
clinical course | 125 |
plasmodium falciparum | 125 |
dna polymerase | 125 |
antibody screening | 125 |
heavy chain | 124 |
blood mononuclear | 124 |
i ifn | 124 |
genomic rna | 124 |
multifocal leukoencephalopathy | 123 |
hiv viral | 123 |
alcohol use | 123 |
structural proteins | 123 |
gastrointestinal tract | 123 |
diagnostic tests | 123 |
east respiratory | 123 |
observational study | 123 |
sample size | 123 |
cd binding | 122 |
significant reduction | 122 |
developed countries | 122 |
patienten mit | 122 |
surface antigen | 122 |
tumor necrosis | 122 |
national institute | 122 |
hiv epidemic | 122 |
national blood | 121 |
cell disease | 121 |
chest pain | 121 |
closely related | 121 |
antiviral activities | 121 |
pneumocystis carinii | 121 |
viral life | 121 |
blood loss | 121 |
binding lectin | 121 |
receptor binding | 121 |
positive selection | 120 |
pediatric patients | 120 |
chronic infection | 120 |
like particles | 120 |
control measures | 120 |
differentially expressed | 119 |
hla class | 119 |
renal transplant | 119 |
critical role | 119 |
western blotting | 119 |
regression analysis | 119 |
patients presenting | 119 |
birth weight | 118 |
autologous blood | 118 |
time points | 118 |
antiviral properties | 118 |
ist die | 118 |
infected cell | 118 |
also used | 118 |
older adults | 118 |
clinical manifestations | 118 |
transmitted infections | 118 |
abdominal pain | 117 |
body fluids | 117 |
binding affinity | 117 |
solid organ | 117 |
ubiquitin ligase | 117 |
viral gene | 117 |
clinically relevant | 117 |
ifitm proteins | 117 |
presenting cells | 117 |
mouse models | 117 |
analysis revealed | 117 |
homeless people | 117 |
renal biopsy | 116 |
care providers | 116 |
secondary structure | 116 |
glycoprotein gp | 116 |
nipah virus | 116 |
pilot study | 116 |
protein synthesis | 116 |
chemokine receptors | 116 |
aged years | 115 |
mg day | 115 |
one case | 115 |
health status | 115 |
cellular proteins | 115 |
hepatocellular carcinoma | 115 |
results obtained | 115 |
antiviral effects | 115 |
per day | 115 |
children aged | 115 |
pulmonary disease | 115 |
will also | 115 |
case series | 115 |
heart failure | 115 |
care services | 114 |
analysis showed | 114 |
leading cause | 114 |
within hours | 114 |
highly sensitive | 114 |
antiretroviral drugs | 114 |
less likely | 114 |
cellular immune | 114 |
patients may | 114 |
among people | 114 |
antiglobulin test | 114 |
pulmonary tuberculosis | 113 |
frozen plasma | 113 |
hiv entry | 113 |
described previously | 113 |
type infection | 113 |
lymph node | 113 |
among men | 113 |
within days | 112 |
tumor cells | 112 |
may play | 112 |
another study | 112 |
world bank | 112 |
hiv treatment | 112 |
hiv envelope | 112 |
prostate cancer | 112 |
acquired pneumonia | 111 |
year period | 111 |
antiviral drug | 111 |
health insurance | 111 |
transcription factors | 111 |
natural history | 111 |
per patient | 111 |
first step | 111 |
female sex | 111 |
upper respiratory | 111 |
factor viii | 111 |
days post | 111 |
donor selection | 111 |
healthy donors | 110 |
organ transplant | 110 |
respiratory failure | 110 |
pandemic influenza | 110 |
cardiac arrest | 110 |
neopterin levels | 109 |
disease virus | 109 |
primary infection | 109 |
three different | 109 |
iron deficiency | 109 |
der hiv | 109 |
renal transplantation | 109 |
allergic rhinitis | 109 |
common cause | 108 |
clinical data | 108 |
hiv env | 108 |
significantly different | 108 |
infection may | 108 |
envelope proteins | 108 |
small number | 108 |
depressive symptoms | 108 |
african american | 108 |
measured using | 108 |
blood centers | 108 |
disease severity | 108 |
phase ii | 108 |
social distancing | 108 |
membrane protein | 108 |
injection drug | 107 |
generation sequencing | 107 |
healthy individuals | 107 |
higher levels | 107 |
among children | 107 |
clinical characteristics | 107 |
sectional study | 107 |
trauma patients | 107 |
stranded dna | 106 |
many countries | 106 |
mrna expression | 106 |
past years | 106 |
viral genomes | 106 |
psychological distress | 106 |
virus rna | 106 |
high frequency | 106 |
infected mice | 106 |
blood service | 106 |
genomic dna | 106 |
signal transduction | 106 |
may help | 106 |
primary health | 105 |
zu einer | 105 |
cells mm | 105 |
neutralizing activity | 105 |
infection among | 105 |
authors declare | 105 |
effective treatment | 105 |
analyzed using | 105 |
different types | 105 |
exposure prophylaxis | 105 |
healthcare providers | 105 |
social support | 105 |
cell cultures | 105 |
antibiotic therapy | 105 |
host proteins | 105 |
herpes virus | 105 |
cmv infection | 104 |
cancer cell | 104 |
data analysis | 104 |
confidence interval | 104 |
bacterial infection | 104 |
three patients | 104 |
health problems | 104 |
medication adherence | 104 |
virus envelope | 104 |
mit einer | 104 |
global burden | 104 |
human disease | 103 |
cell transplantation | 103 |
rna genome | 103 |
two years | 103 |
platelet transfusion | 103 |
future studies | 103 |
hospitalized patients | 103 |
ist eine | 103 |
blood transfusions | 103 |
risk groups | 103 |
lentiviral vectors | 103 |
descriptive abstract | 103 |
naturally occurring | 102 |
early diagnosis | 102 |
much higher | 102 |
hiv rna | 102 |
primary human | 102 |
rbc transfusion | 102 |
fresh frozen | 102 |
inclusion criteria | 102 |
false positive | 102 |
respiratory disease | 102 |
clinical presentation | 102 |
japanese encephalitis | 102 |
restriction factors | 102 |
light chain | 102 |
national institutes | 102 |
clinical use | 101 |
infected persons | 101 |
pneumococcal conjugate | 101 |
hiv self | 101 |
molecular biology | 101 |
also showed | 101 |
broad spectrum | 101 |
significantly decreased | 101 |
additional file | 101 |
cerebrospinal fluid | 101 |
age groups | 101 |
binding proteins | 100 |
prospective cohort | 100 |
studies suggest | 100 |
virus disease | 100 |
positive cells | 100 |
clinical signs | 100 |
infected adults | 100 |
cell type | 99 |
stage renal | 99 |
red cross | 99 |
spectrum antiviral | 99 |
ion channel | 99 |
serum creatinine | 99 |
hcv replication | 99 |
antimicrobial resistance | 99 |
chronic hcv | 99 |
well known | 99 |
chikungunya virus | 99 |
key role | 99 |
treated cells | 99 |
resistant strains | 99 |
gene transfer | 99 |
mechanical ventilation | 98 |
organ transplantation | 98 |
times higher | 98 |
virus transmission | 98 |
virus evolution | 98 |
currently available | 98 |
endemic areas | 98 |
core protein | 98 |
live attenuated | 98 |
body mass | 98 |
plasmid dna | 98 |
pseudomonas aeruginosa | 98 |
sukumo extract | 98 |
may affect | 97 |
zoster virus | 97 |
acute infection | 97 |
aids prevention | 97 |
hcv genotype | 97 |
two weeks | 97 |
large numbers | 97 |
respiratory illness | 97 |
cd receptor | 97 |
physical examination | 97 |
chronic disease | 97 |
case reports | 97 |
extracellular vesicle | 97 |
ed patients | 97 |
blood cultures | 96 |
hela cells | 96 |
rna replication | 96 |
infectious virus | 96 |
dna replication | 96 |
diabetes mellitus | 96 |
autoimmune diseases | 96 |
specific antibody | 96 |
transcriptase inhibitors | 96 |
major cause | 96 |
high rates | 96 |
reading frame | 95 |
transplant patients | 95 |
fold increase | 95 |
real time | 95 |
specific immune | 95 |
growth factors | 95 |
nk cells | 95 |
chronic renal | 95 |
membrane proteins | 94 |
cd expression | 94 |
spike protein | 94 |
also reported | 94 |
like receptors | 94 |
binding domain | 94 |
immune evasion | 94 |
viral membrane | 94 |
statistical significance | 94 |
west africa | 94 |
negative control | 94 |
determined using | 94 |
murine leukemia | 94 |
sialic acid | 94 |
ill patients | 94 |
virus production | 94 |
ciency virus | 93 |
septic shock | 93 |
bis zu | 93 |
six months | 93 |
tat protein | 93 |
medication reconciliation | 93 |
sexual health | 93 |
kommt es | 93 |
influenza infection | 93 |
protective immunity | 93 |
th cells | 93 |
tissue culture | 93 |
young adults | 93 |
medical records | 93 |
human genome | 93 |
drug administration | 93 |
cell spread | 93 |
transmission electron | 93 |
cardiac surgery | 92 |
nitric oxide | 92 |
small interfering | 92 |
heart disease | 92 |
hiv cases | 92 |
rna helicase | 92 |
viral infectivity | 92 |
first months | 92 |
acid sequence | 92 |
humoral immune | 92 |
injecting drug | 92 |
cryptococcus neoformans | 92 |
hand hygiene | 92 |
communicable diseases | 91 |
ed visits | 91 |
mediated immunity | 91 |
virus glycoprotein | 91 |
blood groups | 91 |
siv infection | 91 |
human immune | 91 |
national health | 91 |
tertiary care | 91 |
low cd | 91 |
antibiotic resistance | 91 |
jurkat cells | 91 |
health facilities | 91 |
human herpesvirus | 91 |
und der | 91 |
blood volume | 90 |
york city | 90 |
adaptive immunity | 90 |
transfusion practice | 90 |
differential diagnosis | 90 |
natural killer | 90 |
active site | 90 |
capsid protein | 90 |
immunodefi ciency | 90 |
randomized trial | 90 |
cfu ml | 90 |
different viruses | 90 |
direct contact | 90 |
crucial role | 90 |
exclusion chromatography | 89 |
resistance mutations | 89 |
infected cats | 89 |
including hiv | 89 |
general hospital | 89 |
cell function | 89 |
civil society | 89 |
phase iii | 89 |
cells infected | 89 |
hiv protease | 89 |
transfusion therapy | 89 |
month period | 89 |
quality assurance | 89 |
recipient cells | 89 |
retrospective analysis | 89 |
influenza vaccine | 88 |
tuberculosis infection | 88 |
significant decrease | 88 |
north america | 88 |
fi ndings | 88 |
distress syndrome | 88 |
white blood | 88 |
predictive value | 88 |
cells ml | 88 |
serum samples | 88 |
new hiv | 88 |
healthcare workers | 88 |
cell entry | 88 |
twice daily | 88 |
viral disease | 88 |
proinflammatory cytokines | 88 |
assessed using | 88 |
derived exosomes | 88 |
response rate | 88 |
hiv co | 87 |
studies showed | 87 |
cell viability | 87 |
next generation | 87 |
emerging infections | 87 |
social media | 87 |
sexual transmission | 87 |
ribosomal frameshifting | 87 |
south america | 87 |
positive control | 87 |
gay men | 87 |
harm reduction | 87 |
health problem | 87 |
humanized mouse | 87 |
five patients | 86 |
two cases | 86 |
patient safety | 86 |
cell leukemia | 86 |
clinical samples | 86 |
cells via | 86 |
mast cells | 86 |
converting enzyme | 86 |
transmitted diseases | 86 |
may represent | 86 |
standard deviation | 86 |
therapeutic potential | 86 |
analysis using | 86 |
life expectancy | 85 |
human plasma | 85 |
case fatality | 85 |
entry inhibitors | 85 |
will provide | 85 |
negative patients | 85 |
antibody screen | 85 |
antigen expression | 85 |
among women | 85 |
structural basis | 85 |
nkt cells | 85 |
und die | 85 |
adhesion molecule | 85 |
better understanding | 85 |
respiratory infection | 84 |
reported cases | 84 |
clinical disease | 84 |
ml kg | 84 |
emergency medicine | 84 |
dependent rna | 84 |
highly effective | 84 |
viral vectors | 84 |
health service | 84 |
biological activity | 84 |
current study | 84 |
uninfected children | 84 |
clinical outcome | 84 |
potential role | 84 |
deficient mice | 83 |
inflammatory syndrome | 83 |
human milk | 83 |
care system | 83 |
acute phase | 83 |
patients admitted | 83 |
proviral dna | 83 |
genetic diversity | 83 |
sample preparation | 83 |
young people | 83 |
carinii pneumonia | 83 |
serum levels | 83 |
gold standard | 82 |
lupus erythematosus | 82 |
durch die | 82 |
ic values | 82 |
high incidence | 82 |
gene products | 82 |
chronic kidney | 82 |
see chapter | 82 |
high dose | 82 |
hospital mortality | 82 |
cytoplasmic domain | 82 |
many different | 82 |
von der | 81 |
hpv types | 81 |
inflammatory responses | 81 |
alveolar macrophages | 81 |
fold higher | 81 |
safe blood | 81 |
frameshift efficiency | 81 |
risk behaviors | 81 |
usa introduction | 81 |
low ph | 81 |
evd survivors | 81 |
vero cells | 81 |
internal medicine | 81 |
hospital admission | 81 |
hpv infection | 80 |
based assay | 80 |
per unit | 80 |
tropic hiv | 80 |
time donors | 80 |
high throughput | 80 |
gp binding | 80 |
protein levels | 80 |
cells using | 80 |
positive individuals | 80 |
feline immunodeficiency | 80 |
cell populations | 80 |
transfusion reaction | 80 |
aids related | 80 |
bl cells | 80 |
human health | 80 |
community health | 79 |
donate blood | 79 |
conjugate vaccine | 79 |
cases per | 79 |
cell epitopes | 79 |
restriction factor | 79 |
causative agent | 79 |
poorly understood | 79 |
bronchoalveolar lavage | 79 |
women living | 79 |
data show | 79 |
recent advances | 79 |
months later | 79 |
surface proteins | 79 |
antiviral response | 79 |
group system | 79 |
culture media | 79 |
preventive therapy | 79 |
inhibits hiv | 79 |
signaling pathway | 79 |
virus strains | 79 |
wide variety | 79 |
drug development | 78 |
reconstitution inflammatory | 78 |
sequence analysis | 78 |
time point | 78 |
transmembrane domain | 78 |
systemic lupus | 78 |
preliminary results | 78 |
er stress | 78 |
working group | 78 |
treatment options | 78 |
vital signs | 78 |
infl uenza | 78 |
linear regression | 78 |
lung disease | 78 |
guinea pigs | 78 |
early stages | 78 |
acid residues | 78 |
private sector | 78 |
type diabetes | 77 |
cell transmission | 77 |
female donors | 77 |
codon usage | 77 |
haemophilus influenzae | 77 |
acquired immune | 77 |
greater risk | 77 |
developing world | 77 |
high sensitivity | 77 |
candida albicans | 77 |
virus release | 77 |
health issues | 77 |
genital herpes | 77 |
broad range | 77 |
folic acid | 77 |
vitro studies | 77 |
voluntary blood | 77 |
inhibit viral | 77 |
genetic variation | 77 |
dengue fever | 77 |
antimicrobial agents | 77 |
immune complexes | 77 |
severe covid | 77 |
immune cell | 77 |
using two | 76 |
health policy | 76 |
cells may | 76 |
severe cases | 76 |
chronic viral | 76 |
will help | 76 |
may include | 76 |
many viruses | 76 |
high mortality | 76 |
serum albumin | 76 |
massive transfusion | 76 |
inhibitory effects | 76 |
study population | 76 |
also tested | 76 |
pathogen inactivation | 76 |
vaccine candidates | 76 |
evidence suggests | 76 |
chronic obstructive | 76 |
remains unclear | 75 |
th day | 75 |
prevent hiv | 75 |
single dose | 75 |
buffy coat | 75 |
monoclonal anti | 75 |
replication cycle | 75 |
cd bs | 75 |
lymphoid tissue | 75 |
will continue | 75 |
antibody identification | 75 |
die diagnose | 75 |
many patients | 75 |
data collected | 75 |
viral glycoproteins | 74 |
results demonstrate | 74 |
coronavirus infection | 74 |
entry inhibitor | 74 |
service delivery | 74 |
urine samples | 74 |
fusion inhibitors | 74 |
control study | 74 |
bovine serum | 74 |
high degree | 74 |
major histocompatibility | 74 |
medical record | 74 |
least two | 74 |
icu admission | 74 |
shock syndrome | 74 |
mit der | 74 |
protective effect | 74 |
controlled trials | 73 |
central role | 73 |
lymphocyte count | 73 |
transmembrane protein | 73 |
falciparum malaria | 73 |
antigen presenting | 73 |
epithelial cell | 73 |
mouth disease | 73 |
time period | 73 |
type lectin | 73 |
healthy volunteers | 73 |
contact tracing | 73 |
increased expression | 73 |
among others | 73 |
molecular basis | 73 |
direct antiglobulin | 73 |
surface markers | 73 |
human coronavirus | 73 |
five years | 73 |
virus detection | 73 |
flow cytometric | 73 |
blood banking | 73 |
clinical isolates | 73 |
chronic diseases | 73 |
study aimed | 73 |
two major | 73 |
binding activity | 73 |
two types | 73 |
condom use | 73 |
data elements | 73 |
replacement therapy | 73 |
donor screening | 73 |
chronically infected | 73 |
family history | 73 |
highly pathogenic | 73 |
relatively high | 73 |
health research | 72 |
information system | 72 |
based vaccine | 72 |
based assays | 72 |
many studies | 72 |
hcv core | 72 |
rna helicases | 72 |
kidney transplant | 72 |
old female | 72 |
early detection | 72 |
african countries | 72 |
antiviral agent | 72 |
lopinavir ritonavir | 72 |
tested positive | 72 |
health professionals | 72 |
derived macrophages | 72 |
cells treated | 72 |
human serum | 72 |
sexual partners | 72 |
allergic reactions | 72 |
cell membranes | 72 |
group i | 72 |
i molecules | 72 |
cellular immunity | 72 |
dna virus | 72 |
better understand | 72 |
terminal region | 72 |
derived extracellular | 71 |
latent infection | 71 |
competing interests | 71 |
plasma cells | 71 |
size exclusion | 71 |
active tuberculosis | 71 |
become infected | 71 |
host defense | 71 |
age years | 71 |
well established | 71 |
nuclear import | 71 |
chronic hiv | 71 |
antibiotic treatment | 71 |
cell subsets | 71 |
intravenous drug | 71 |
heart rate | 71 |
neutralizing human | 71 |
odds ratio | 71 |
two distinct | 71 |
among young | 71 |
interfering rna | 71 |
hemolytic transfusion | 71 |
flow assay | 71 |
new antiviral | 70 |
open reading | 70 |
surface area | 70 |
infections caused | 70 |
clinical significance | 70 |
nucleotide sequence | 70 |
recombinant human | 70 |
hemolytic anemia | 70 |
major role | 70 |
multiple sclerosis | 70 |
will require | 70 |
pathogen reduction | 70 |
human monocytes | 70 |
low birth | 70 |
delivery systems | 70 |
rabies virus | 70 |
mycobacterium avium | 70 |
expressing cells | 70 |
glomerular filtration | 70 |
brain barrier | 70 |
persistent infection | 70 |
studies show | 70 |
emerging viruses | 69 |
density gradient | 69 |
myocardial infarction | 69 |
higher rates | 69 |
cultured cells | 69 |
cell development | 69 |
disease caused | 69 |
genetic material | 69 |
machine learning | 69 |
aids vaccine | 69 |
opportunistic infection | 69 |
may increase | 69 |
rheumatoid arthritis | 69 |
resistant staphylococcus | 69 |
many cases | 69 |
low risk | 69 |
thermo fisher | 69 |
vast majority | 69 |
liver transplantation | 69 |
based hiv | 69 |
blood sample | 69 |
ns protein | 69 |
old male | 69 |
potent anti | 69 |
will likely | 69 |
specific ige | 68 |
made available | 68 |
effector cells | 68 |
urban areas | 68 |
per se | 68 |
use among | 68 |
der patienten | 68 |
recently reported | 68 |
mutation rates | 68 |
relative risk | 68 |
increased levels | 68 |
vor allem | 68 |
rhd gene | 68 |
drug therapy | 68 |
case study | 68 |
using different | 68 |
obstructive pulmonary | 68 |
rhesus macaque | 68 |
fatality rate | 68 |
studies using | 68 |
clinical pharmacist | 68 |
higher prevalence | 68 |
european countries | 68 |
aids research | 68 |
conformational change | 68 |
virus ns | 68 |
two decades | 68 |
climate change | 68 |
negative bacteria | 68 |
new cases | 68 |
infected patient | 68 |
aids pandemic | 68 |
mit einem | 67 |
without hiv | 67 |
patient population | 67 |
normal range | 67 |
donated blood | 67 |
premature infants | 67 |
one week | 67 |
previously shown | 67 |
expression level | 67 |
infected women | 67 |
pneumococcal carriage | 67 |
mass index | 67 |
kidney injury | 67 |
first case | 67 |
serious adverse | 67 |
laboratory tests | 67 |
limited number | 67 |
likely due | 67 |
dna synthesis | 67 |
child health | 67 |
may present | 67 |
atopic dermatitis | 67 |
elderly patients | 67 |
natural products | 67 |
gene silencing | 66 |
viral pathogenesis | 66 |
st century | 66 |
population size | 66 |
sequence data | 66 |
antiviral compounds | 66 |
new infections | 66 |
genome sequencing | 66 |
will need | 66 |
reproductive health | 66 |
escape mutants | 66 |
future research | 66 |
based vaccines | 66 |
hcv ns | 66 |
liver failure | 66 |
long terminal | 66 |
cov infection | 66 |
vaccine efficacy | 66 |
mutation rate | 66 |
speci fi | 66 |
gestational age | 66 |
preliminary data | 66 |
social isolation | 66 |
limited settings | 66 |
rna binding | 66 |
umbilical cord | 66 |
plasma levels | 66 |
virus binding | 66 |
will allow | 66 |
antibody titers | 65 |
th erapie | 65 |
urgent need | 65 |
renal involvement | 65 |
chart review | 65 |
pseudotyped hiv | 65 |
rna synthesis | 65 |
literature review | 65 |
study shows | 65 |
i ii | 65 |
single cell | 65 |
cytomegalovirus infection | 65 |
kidney transplantation | 65 |
one month | 65 |
group ii | 65 |
intravenous immunoglobulin | 65 |
three months | 65 |
cpg dinucleotides | 65 |
new public | 65 |
similar results | 65 |
viral capsid | 65 |
also shown | 65 |
physical health | 65 |
nk cell | 65 |
genital tract | 65 |
matrix protein | 65 |
specific ctl | 65 |
therapeutic agents | 65 |
lyme disease | 65 |
ferritin levels | 65 |
fi ciency | 65 |
antiviral immune | 65 |
receptor expression | 65 |
quantitative real | 65 |
three groups | 65 |
capsid proteins | 65 |
antibody production | 65 |
hiv hcv | 65 |
sierra leone | 65 |
environmental factors | 64 |
industrialized countries | 64 |
pseudotyped viruses | 64 |
teaching hospital | 64 |
renal insufficiency | 64 |
median time | 64 |
human body | 64 |
tropical diseases | 64 |
high fever | 64 |
mediated immune | 64 |
sexual risk | 64 |
many years | 64 |
toxic shock | 64 |
potent inhibitors | 64 |
hepatitis virus | 64 |
reference laboratory | 64 |
oxygen saturation | 64 |
flow assays | 64 |
evaluated using | 64 |
may explain | 64 |
relatively low | 64 |
respiratory symptoms | 64 |
potent antiviral | 64 |
protein interaction | 64 |
ev isolation | 64 |
phylogenetic analysis | 64 |
descriptive statistics | 64 |
wound healing | 64 |
disease transmission | 64 |
trypsin inhibitor | 64 |
signal amplification | 64 |
specific binding | 64 |
significant effect | 63 |
small rna | 63 |
medical research | 63 |
well plates | 63 |
liver fibrosis | 63 |
high rate | 63 |
pneumococcal disease | 63 |
take place | 63 |
nuclear export | 63 |
potential therapeutic | 63 |
studies will | 63 |
healthy subjects | 63 |
additive solution | 63 |
bacterial growth | 63 |
also performed | 63 |
disease outbreaks | 63 |
total rna | 63 |
retrospective cohort | 63 |
multivariate analysis | 63 |
also occur | 63 |
significant changes | 63 |
may become | 63 |
influenza pandemic | 63 |
gel electrophoresis | 63 |
induced apoptosis | 63 |
skin test | 63 |
cell carcinoma | 63 |
smooth muscle | 63 |
th century | 63 |
cystic fibrosis | 63 |
less common | 63 |
much lower | 63 |
histocompatibility complex | 63 |
advanced hiv | 63 |
delivery system | 63 |
latently infected | 63 |
stromal cells | 63 |
hsp inhibitors | 63 |
buffy coats | 62 |
terminal repeat | 62 |
blood culture | 62 |
also demonstrated | 62 |
clinical pharmacy | 62 |
viral antigens | 62 |
autoimmune disease | 62 |
cell receptors | 62 |
blood type | 62 |
human immunodefi | 62 |
type gp | 62 |
cd lymphocyte | 62 |
may serve | 62 |
increasing number | 62 |
human infection | 62 |
protein interactions | 62 |
healthy children | 62 |
transfusion safety | 62 |
potential risk | 62 |
acid amplification | 62 |
combination antiretroviral | 62 |
terminal domain | 62 |
southeast asia | 62 |
cell depletion | 62 |
plasma exchange | 62 |
three years | 62 |
lymphoid tissues | 62 |
independently associated | 62 |
different stages | 62 |
patients showed | 62 |
blot analysis | 62 |
risk assessment | 62 |
skin lesions | 62 |
care units | 62 |
randomly selected | 62 |
past decade | 62 |
fisher scientific | 62 |
two main | 62 |
rna levels | 62 |
case management | 62 |
liver transplant | 62 |
potent hiv | 61 |
auf die | 61 |
immune function | 61 |
mice infected | 61 |
significantly improved | 61 |
policy makers | 61 |
rhce ce | 61 |
virus particle | 61 |
average age | 61 |
healthcare system | 61 |
well plate | 61 |
ebov gp | 61 |
much less | 61 |
herpes zoster | 61 |
single nucleotide | 61 |
high quality | 61 |
million deaths | 61 |
gold nanoparticle | 61 |
tb patients | 61 |
pleural effusion | 61 |
quantitative pcr | 61 |
respiratory virus | 61 |
progenitor cells | 61 |
active tb | 61 |
retrospective review | 61 |
antimicrobial therapy | 61 |
organ failure | 61 |
platelet products | 61 |
treated patients | 61 |
chronic liver | 61 |
well documented | 61 |
bact alert | 61 |
human antibody | 61 |
acute kidney | 61 |
surface protein | 61 |
dna damage | 61 |
lung injury | 61 |
new class | 61 |
human diseases | 61 |
immunosorbent assay | 61 |
expressed breast | 61 |
human blood | 61 |
close contact | 61 |
gag protein | 61 |
low level | 61 |
metal nanoparticles | 61 |
infectious agent | 61 |
blood plasma | 61 |
indirect antiglobulin | 60 |
storage time | 60 |
latin america | 60 |
bal fluid | 60 |
intercellular communication | 60 |
human influenza | 60 |
infected subjects | 60 |
study conducted | 60 |
high viral | 60 |
blood screening | 60 |
rna molecules | 60 |
last decade | 60 |
ctl responses | 60 |
patients suffering | 60 |
nucleoside reverse | 60 |
pneumocystis jirovecii | 60 |
analysed using | 60 |
first year | 60 |
study subjects | 60 |
effective vaccine | 60 |
interfering rnas | 60 |
disease burden | 60 |
virus dna | 60 |
end stage | 60 |
physical distancing | 60 |
host disease | 60 |
detection limit | 60 |
myeloid cells | 60 |
skin testing | 60 |
took place | 60 |
inhibited hiv | 60 |
also present | 60 |
widespread use | 60 |
abo blood | 60 |
medical history | 60 |
transmission dynamics | 59 |
rift valley | 59 |
viral particle | 59 |
cmv disease | 59 |
newly diagnosed | 59 |
related diseases | 59 |
essential role | 59 |
clinical development | 59 |
differential expression | 59 |
platelet counts | 59 |
international community | 59 |
viral strains | 59 |
point mutations | 59 |
new therapeutic | 59 |
associated nephropathy | 59 |
fi tness | 59 |
cell lysates | 59 |
cell differentiation | 59 |
rna silencing | 59 |
infection rates | 59 |
effector functions | 59 |
uninfected individuals | 59 |
human viruses | 59 |
clinical setting | 59 |
lower levels | 59 |
confidence intervals | 59 |
alcohol consumption | 59 |
infected people | 59 |
reactive protein | 59 |
mortality among | 59 |
ct scan | 59 |
seasonal influenza | 59 |
cell survival | 59 |
genome replication | 59 |
nachweis von | 59 |
care settings | 59 |
diagnostic test | 59 |
light chains | 59 |
older people | 59 |
flow strip | 59 |
abstract withdrawn | 59 |
molecular mechanism | 58 |
disease prevention | 58 |
nach der | 58 |
mechanisms underlying | 58 |
coding region | 58 |
art adherence | 58 |
cellular uptake | 58 |
different cell | 58 |
units per | 58 |
significant correlation | 58 |
rural areas | 58 |
lessons learned | 58 |
transfused patients | 58 |
rights reserved | 58 |
valley fever | 58 |
negative controls | 58 |
lipid bilayer | 58 |
viral genes | 58 |
surveillance system | 58 |
deficiency syndrome | 58 |
first line | 58 |
influenza hemagglutinin | 58 |
incidence rate | 58 |
flow cytometer | 58 |
tumour cells | 58 |
plasma units | 58 |
im liquor | 58 |
fractional order | 58 |
cell population | 58 |
may influence | 58 |
respiratory viral | 58 |
four patients | 58 |
health authorities | 58 |
significant association | 58 |
time series | 58 |
disease surveillance | 58 |
smoking cessation | 58 |
ethics committee | 58 |
aber auch | 57 |
mit dem | 57 |
per month | 57 |
different mechanisms | 57 |
oral bioavailability | 57 |
mean number | 57 |
important cause | 57 |
routine use | 57 |
treatment failure | 57 |
chinese government | 57 |
hours post | 57 |
size distribution | 57 |
positive women | 57 |
tested using | 57 |
within months | 57 |
apheresis platelets | 57 |
vitro activity | 57 |
calculated using | 57 |
birth defects | 57 |
adverse outcomes | 57 |
mast cell | 57 |
san francisco | 57 |
nonhuman primates | 57 |
hospital transfusion | 57 |
another example | 57 |
associated protein | 57 |
pcr assay | 57 |
retroviral therapy | 57 |
hla antibodies | 57 |
viral escape | 57 |
primer sets | 57 |
linked immunosorbent | 57 |
chronic hbv | 57 |
haemorrhagic fever | 57 |
bei kindern | 57 |
data dictionary | 57 |
hospital stay | 57 |
drug design | 57 |
positive result | 57 |
culture medium | 57 |
susceptibility testing | 57 |
months post | 57 |
serine protease | 57 |
socioeconomic status | 57 |
isolated using | 56 |
der regel | 56 |
inkt cells | 56 |
cell therapy | 56 |
immunodeficiency viruses | 56 |
severe sepsis | 56 |
bacterial pathogens | 56 |
proteins involved | 56 |
ef fi | 56 |
clinical improvement | 56 |
murine model | 56 |
task force | 56 |
filtration rate | 56 |
toxoplasma gondii | 56 |
culture supernatant | 56 |
cell migration | 56 |
study using | 56 |
set point | 56 |
tissue damage | 56 |
one hundred | 56 |
correctional health | 56 |
major challenge | 56 |
also associated | 56 |
may require | 56 |
probably due | 56 |
producing cells | 56 |
gp envelope | 56 |
drinking water | 56 |
viral shedding | 56 |
serum ferritin | 56 |
chlamydia trachomatis | 56 |
increased incidence | 56 |
antifungal therapy | 56 |
cell adhesion | 56 |
decision making | 56 |
drug abuse | 56 |
nonstructural protein | 56 |
natural infection | 56 |
pcr amplification | 56 |
oral administration | 55 |
eight patients | 55 |
blood management | 55 |
effective vaccines | 55 |
significant improvement | 55 |
side chain | 55 |
surveillance data | 55 |
different viral | 55 |
several years | 55 |
bacterial vaginosis | 55 |
antibody levels | 55 |
hb level | 55 |
sexual contact | 55 |
repeat donors | 55 |
may reduce | 55 |
hiv risk | 55 |
lymphotropic virus | 55 |
infected animals | 55 |
physical activity | 55 |
clinical settings | 55 |
preventive measures | 55 |
promoter region | 55 |
hiv antibody | 55 |
past months | 55 |
peritoneal dialysis | 55 |
specific primers | 55 |
frequently used | 55 |
virus assembly | 55 |
conditioned media | 55 |
infections among | 55 |
column agglutination | 55 |
clinical response | 55 |
infi ltration | 55 |
data obtained | 55 |
prospective observational | 55 |
complete remission | 55 |
hiv antibodies | 55 |
samples tested | 55 |
potent inhibitor | 55 |
productive infection | 55 |
type envelope | 55 |
vivo studies | 55 |
clinical applications | 55 |
receptor ccr | 54 |
deep sequencing | 54 |
screening test | 54 |
channel activity | 54 |
safety profile | 54 |
scansystem tm | 54 |
hiv test | 54 |
first two | 54 |
lymphocytic choriomeningitis | 54 |
acute hepatitis | 54 |
regional blood | 54 |
surface plasmon | 54 |
proteasomal degradation | 54 |
clostridium difficile | 54 |
high doses | 54 |
reagent program | 54 |
gene encoding | 54 |
positive correlation | 54 |
study found | 54 |
igg antibodies | 54 |
selective pressure | 54 |
outcomes among | 54 |
soft tissue | 54 |
group antigens | 54 |
extracellular matrix | 54 |
patients aged | 54 |
ltr promoter | 54 |
platelet aggregation | 54 |
may need | 54 |
potential impact | 54 |
oral cavity | 54 |
resistant bacteria | 54 |
may reflect | 54 |
surface receptors | 54 |
study demonstrated | 54 |
cause disease | 54 |
like protease | 54 |
inflammatory cytokine | 54 |
global hiv | 54 |
helicobacter pylori | 54 |
type hiv | 54 |
shock proteins | 54 |
inflammatory diseases | 53 |
negative blood | 53 |
data set | 53 |
cmv retinitis | 53 |
acid substitutions | 53 |
among different | 53 |
patient blood | 53 |
increased significantly | 53 |
best practices | 53 |
general practitioners | 53 |
sex work | 53 |
type iii | 53 |
genes involved | 53 |
common causes | 53 |
regression model | 53 |
blood flow | 53 |
clinical efficacy | 53 |
luciferase activity | 53 |
platelets stored | 53 |
patients hospitalized | 53 |
pivotal role | 53 |
genes encoding | 53 |
reporter gene | 53 |
base pairs | 53 |
two studies | 53 |
rhodococcus equi | 53 |
hcv infections | 53 |
oxygen species | 53 |
hcv hiv | 53 |
infected individual | 53 |
immune systems | 53 |
gene delivery | 53 |
inject drugs | 53 |
well understood | 53 |
among homeless | 53 |
primary outcome | 53 |
lipid raft | 53 |
host response | 53 |
visceral leishmaniasis | 53 |
transfusion transmitted | 53 |
function tests | 53 |
quality management | 53 |
plasmacytoid dendritic | 53 |
viral clearance | 53 |
key populations | 53 |
cd lymphocytes | 53 |
compared using | 53 |
substance abuse | 53 |
studies indicate | 53 |
scientific community | 53 |
reactive oxygen | 53 |
liver biopsy | 53 |
included patients | 53 |
human pathogens | 53 |
prevalence among | 53 |
alkaline phosphatase | 53 |
might also | 53 |
clinical diagnosis | 53 |
solid phase | 53 |
jakob disease | 53 |
acute rejection | 52 |
also cause | 52 |
human macrophages | 52 |
fetal dna | 52 |
lg ml | 52 |
also important | 52 |
abo rh | 52 |
donor samples | 52 |
important roles | 52 |
ctl response | 52 |
last months | 52 |
increased susceptibility | 52 |
also increased | 52 |
cellular factors | 52 |
viral surface | 52 |
cells showed | 52 |
hiv diagnosis | 52 |
uninfected cells | 52 |
liver injury | 52 |
give rise | 52 |
advisory committee | 52 |
varicella zoster | 52 |
drug treatment | 52 |
study also | 52 |
luciferase reporter | 52 |
russian federation | 52 |
effective antiviral | 52 |
highly variable | 52 |
spinal cord | 52 |
throughput screening | 52 |
virulence evolution | 52 |
hiv drug | 52 |
cell wall | 52 |
blood cd | 52 |
viruses may | 52 |
previous study | 52 |
high resolution | 52 |
hiv among | 52 |
protein complex | 52 |
interferon response | 52 |
chronic infections | 52 |
interferon alpha | 52 |
laboratory testing | 52 |
medical treatment | 52 |
immune suppression | 52 |
done using | 52 |
ccr expression | 52 |
cell transplant | 52 |
new insights | 52 |
malaria control | 52 |
endothelial cell | 52 |
available data | 52 |
fluorescent protein | 52 |
drug resistant | 52 |
homosexual men | 52 |
linked glycosylation | 51 |
uric acid | 51 |
neisseria gonorrhoeae | 51 |
human peripheral | 51 |
positive dat | 51 |
coinfected patients | 51 |
response rates | 51 |
current status | 51 |
renal impairment | 51 |
among msm | 51 |
algal lectins | 51 |
six patients | 51 |
research center | 51 |
cytoplasmic tail | 51 |
human population | 51 |
pcr products | 51 |
stimulating factor | 51 |
parainfluenza virus | 51 |
promoter activity | 51 |
condomless sex | 51 |
trima accel | 51 |
small intestine | 51 |
applied biosystems | 51 |
acid sequences | 51 |
universal arv | 51 |
pulmonary infections | 51 |
patient samples | 51 |
nef gene | 51 |
iron supplementation | 51 |
unclear whether | 51 |
initial infection | 51 |
herpes viruses | 51 |
glycosylation sites | 51 |
tmp smx | 51 |
nasal spray | 51 |
rich plasma | 51 |
weeks later | 51 |
heparan sulfate | 51 |
patient outcomes | 51 |
cd receptors | 51 |
human respiratory | 51 |
protein folding | 51 |
fully automated | 51 |
segmental glomerulosclerosis | 51 |
time spent | 51 |
survival rate | 51 |
liver function | 51 |
protein gp | 51 |
hiv acquisition | 51 |
strand transfer | 51 |
adverse event | 51 |
donor blood | 51 |
hiv incidence | 51 |
data element | 51 |
cell growth | 51 |
mediated endocytosis | 51 |
complement activation | 51 |
otitis media | 51 |
viral transmission | 51 |
transmission via | 51 |
sting pathway | 51 |
focal segmental | 51 |
pneumocystis pneumonia | 51 |
side effect | 51 |
durch den | 50 |
male donors | 50 |
older age | 50 |
years later | 50 |
first study | 50 |
influenza vaccination | 50 |
clinical study | 50 |
fl uid | 50 |
comparative study | 50 |
ist der | 50 |
risk reduction | 50 |
gi tract | 50 |
pattern recognition | 50 |
cellular processes | 50 |
two days | 50 |
cell concentrates | 50 |
electronic medical | 50 |
plt count | 50 |
several different | 50 |
gene product | 50 |
virus load | 50 |
plasmon resonance | 50 |
renal tubular | 50 |
human host | 50 |
higher mortality | 50 |
antiviral immunity | 50 |
novel antiviral | 50 |
pseudotyped virus | 50 |
window period | 50 |
highly expressed | 50 |
correlation coefficient | 50 |
fi rst | 50 |
secondary structures | 50 |
chronic inflammation | 50 |
pregnant woman | 50 |
experimental data | 50 |
type virus | 50 |
economic impact | 50 |
different concentrations | 50 |
vg vd | 50 |
dna sequences | 50 |
peer review | 50 |
recent data | 50 |
information regarding | 50 |
vaccine delivery | 50 |
several viruses | 50 |
hiv service | 50 |
chest radiograph | 50 |
hepatitis viruses | 50 |
health needs | 50 |
cells transfected | 50 |
situ hybridization | 50 |
host range | 50 |
frameshift site | 50 |
soluble cd | 50 |
lamina propria | 50 |
mrna levels | 50 |
severe respiratory | 50 |
highly potent | 50 |
disease outbreak | 50 |
remains unknown | 50 |
short period | 49 |
secondary distribution | 49 |
primary isolates | 49 |
health education | 49 |
gp protein | 49 |
ethnic groups | 49 |
renal dysfunction | 49 |
bacterial meningitis | 49 |
investigate whether | 49 |
steroid therapy | 49 |
term follow | 49 |
new vaccine | 49 |
following infection | 49 |
helix bundle | 49 |
patients using | 49 |
medical students | 49 |
novel human | 49 |
low hb | 49 |
single donor | 49 |
cohort studies | 49 |
tyrosine kinase | 49 |
hydrogen bonds | 49 |
potential antiviral | 49 |
proteomic analysis | 49 |
per week | 49 |
lesser extent | 49 |
transfected cells | 49 |
systematic analysis | 49 |
viral spread | 49 |
liquid chromatography | 49 |
blood system | 49 |
showed significant | 49 |
hiv drugs | 49 |
blood centre | 49 |
donor population | 49 |
study participants | 49 |
low cost | 49 |
mg daily | 49 |
resource settings | 49 |
transition state | 49 |
genome sequence | 49 |
stress response | 49 |
pathogenic viruses | 49 |
infections may | 49 |
viral hemorrhagic | 49 |
resistant tuberculosis | 49 |
oral health | 49 |
lymphocyte counts | 49 |
storage period | 49 |
assay using | 49 |
viral mrna | 49 |
low dose | 49 |
hiv women | 49 |
host protein | 49 |
square test | 49 |
laboratory findings | 49 |
different methods | 49 |
human metapneumovirus | 49 |
lassa fever | 49 |
assess whether | 49 |
people worldwide | 49 |
hemolytic disease | 49 |
intervention group | 49 |
iron overload | 48 |
among female | 48 |
infectious complications | 48 |
kaposi sarcoma | 48 |
one hand | 48 |
facs analysis | 48 |
therapeutic strategies | 48 |
molecular epidemiology | 48 |
biologically active | 48 |
sexual behavior | 48 |
days later | 48 |
virus genome | 48 |
using flow | 48 |
commercial sex | 48 |
low frequency | 48 |
particle size | 48 |
nuclear factor | 48 |
blood establishments | 48 |
cause severe | 48 |
i interferons | 48 |
clinical management | 48 |
treated rbcs | 48 |
risk behavior | 48 |
expression vector | 48 |
immune recognition | 48 |
liver cirrhosis | 48 |
recognition receptors | 48 |
university school | 48 |
antigen processing | 48 |
negative results | 48 |
among adults | 48 |
derived peptides | 48 |
bei hiv | 48 |
cellular membranes | 48 |
platelet function | 48 |
newly emerging | 48 |
least three | 48 |
control groups | 48 |
institutional support | 48 |
outer membrane | 48 |
primary hiv | 48 |
short hairpin | 48 |
viral nucleic | 48 |
viral transcription | 48 |
cellular protein | 48 |
high titer | 48 |
conducted using | 48 |
young women | 48 |
pol gene | 48 |
rat model | 48 |
protective immune | 48 |
plant extracts | 48 |
fusion inhibitor | 48 |
study suggests | 48 |
patients compared | 48 |
binding agents | 48 |
invasive pneumococcal | 48 |
th percentile | 48 |
european union | 48 |
table shows | 48 |
fusion peptides | 48 |
cell transfusion | 48 |
national hiv | 48 |
culture supernatants | 48 |
among persons | 47 |
surveillance systems | 47 |
virus hemagglutinin | 47 |
molecular dynamics | 47 |
last two | 47 |
emerging viral | 47 |
critical care | 47 |
practice guidelines | 47 |
mobile phone | 47 |
using standard | 47 |
investigated whether | 47 |
among blood | 47 |
social services | 47 |
common among | 47 |
therapeutic effect | 47 |
scid mice | 47 |
allogeneic blood | 47 |
differential ultracentrifugation | 47 |
elevated levels | 47 |
african americans | 47 |
env protein | 47 |
pediatric nephrology | 47 |
resistant hiv | 47 |
marburg virus | 47 |
target dna | 47 |
medical school | 47 |
type replication | 47 |
disease study | 47 |
immune escape | 47 |
magnetic resonance | 47 |
brain injury | 47 |
gel test | 47 |
high concentrations | 47 |
associated coronavirus | 47 |
improve patient | 47 |
rapid detection | 47 |
cynomolgus macaques | 47 |
knockout mice | 47 |
colorectal cancer | 47 |
major problem | 47 |
evs derived | 47 |
virus vaccine | 47 |
tumor growth | 47 |
strongly associated | 47 |
early hiv | 47 |
syncytium formation | 47 |
los angeles | 47 |
east asia | 47 |
significant impact | 47 |
medical staff | 47 |
derived products | 47 |
small extracellular | 47 |
therapeutic target | 47 |
isothermal amplification | 47 |
apoptotic cells | 47 |
arv access | 47 |
chronic diarrhea | 47 |
saudi arabia | 47 |
rhd negative | 47 |
ebola viruses | 47 |
new host | 47 |
several weeks | 47 |
antiviral treatment | 47 |
new drugs | 47 |
listeria monocytogenes | 47 |
bd biosciences | 47 |
iron stores | 47 |
residual risk | 47 |
rbc transfusions | 47 |
passive immunization | 47 |
data sets | 47 |
immunosuppressive therapy | 46 |
transfusion recipients | 46 |
laboratory data | 46 |
large amounts | 46 |
study included | 46 |
therapeutic plasma | 46 |
currently used | 46 |
rna structure | 46 |
center background | 46 |
institutional review | 46 |
animal experiments | 46 |
cardiovascular diseases | 46 |
large scale | 46 |
recombinant proteins | 46 |
creative commons | 46 |
cytopathic effect | 46 |
control cells | 46 |
cell antigens | 46 |
high school | 46 |
hairpin rna | 46 |
plasma hiv | 46 |
weight gain | 46 |
prevent infection | 46 |
randomised controlled | 46 |
health conditions | 46 |
sendai virus | 46 |
protein complexes | 46 |
pulmonary tb | 46 |
successfully used | 46 |
screening tests | 46 |
der nachweis | 46 |
among adolescents | 46 |
often associated | 46 |
care systems | 46 |
cancer therapy | 46 |
cell epitope | 46 |
old boy | 46 |
disease may | 46 |
confocal microscopy | 46 |
less effective | 46 |
bei den | 46 |
associated virus | 46 |
core antigen | 46 |
membrane vesicles | 46 |
magnetic nanoparticles | 46 |
positive donors | 46 |
free energy | 46 |
takes place | 46 |
ct scanning | 46 |
like illness | 46 |
fusion pore | 46 |
human populations | 46 |
risk group | 46 |
increased mortality | 46 |
risk patients | 46 |
life threatening | 46 |
patient received | 46 |
seven patients | 46 |
higher incidence | 46 |
successful treatment | 46 |
heptad repeat | 46 |
healthy adults | 46 |
iron depletion | 46 |
obtained using | 46 |
related quality | 46 |
cell units | 46 |
binding specificity | 46 |
associated herpesvirus | 46 |
van der | 46 |
data demonstrate | 46 |
human lung | 46 |
ethnic minority | 46 |
will lead | 46 |
population health | 46 |
effective therapy | 46 |
rhd genotyping | 46 |
polymerase ii | 46 |
neutralizing hiv | 45 |
older children | 45 |
packed red | 45 |
hiv fusion | 45 |
significantly less | 45 |
und oder | 45 |
evidence indicates | 45 |
exclusion criteria | 45 |
copyright holder | 45 |
lactate dehydrogenase | 45 |
hiv negative | 45 |
two independent | 45 |
surface glycoprotein | 45 |
antibody test | 45 |
chronic inflammatory | 45 |
main protease | 45 |
platelet units | 45 |
new vaccines | 45 |
aids diagnosis | 45 |
may allow | 45 |
data regarding | 45 |
iga nephropathy | 45 |
vaccine candidate | 45 |
also called | 45 |
total protein | 45 |
enveloped virus | 45 |
acute hiv | 45 |
democratic republic | 45 |
cell immunity | 45 |
research institute | 45 |
significant antibodies | 45 |
medicinal chemistry | 45 |
auf eine | 45 |
post transfusion | 45 |
therapeutic options | 45 |
promising results | 45 |
people infected | 45 |
infants born | 45 |
aids response | 45 |
immunode fi | 45 |
possible role | 45 |
emerging diseases | 45 |
puerto rico | 45 |
also determined | 45 |
observational studies | 45 |
last year | 45 |
also play | 45 |
chaperone activity | 45 |
disease course | 45 |
three days | 45 |
whole genome | 45 |
also included | 45 |
wide spectrum | 45 |
false negative | 45 |
blood testing | 45 |
cellular receptor | 45 |
coagulation factors | 45 |
collected data | 45 |
memory cd | 45 |
ev markers | 45 |
related deaths | 45 |
fold change | 45 |
treatment strategies | 45 |
using anti | 45 |
blood count | 45 |
single amino | 45 |
positive donations | 45 |
apheresis platelet | 45 |
molecular docking | 45 |
patients whose | 45 |
humoral immunity | 45 |
lipid bilayers | 45 |
optimal control | 44 |
mannose binding | 44 |
antiviral therapies | 44 |
hivinfected patients | 44 |
kj mol | 44 |
platelet pools | 44 |
clinical specimens | 44 |
also evaluated | 44 |
mainly due | 44 |
testing among | 44 |
display technology | 44 |
hemorrhagic fevers | 44 |
sequencing data | 44 |
body temperature | 44 |
children years | 44 |
high hiv | 44 |
acute viral | 44 |
dengue hemorrhagic | 44 |
intercellular adhesion | 44 |
isolated evs | 44 |
surgical procedures | 44 |
equine encephalitis | 44 |
large proportion | 44 |
virus may | 44 |
international license | 44 |
fungal infection | 44 |
rational design | 44 |